BioAffinity Technologies (BIAF) announced that the Australian Patent Office has accepted a patent application for the company’s proprietary platform technology for assessing lung health and predicting the likelihood of multiple lung diseases in patients. The patent application covers methods that use flow cytometry combined with fluorescent probes, molecular “tags” that attach to specific cell types, to detect cellular and molecular signatures of multiple lung diseases.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Secures Australian Patent for Lung Health
- bioAffinity Technologies Advances Non-Invasive Lung Cancer Diagnostic Study
- bioAffinity Technologies Advances Lung Cancer Detection with Innovative Study
- bioAffinity Technologies Presents at CHEST 2025 Conference
- bioAffinity Technologies Secures Patent for Lung Cancer Detection